Haoxi Health Technology (HAO) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
29 Nov, 2025Company overview and business model
Operates as an online marketing solution provider in China, primarily serving healthcare industry advertisers through short video and digital ad placements on major platforms like ByteDance's Ocean Engine, Douyin, and Toutiao.
Offers one-stop, customized marketing services including ad planning, production, placement, and optimization, leveraging proprietary data analysis software, Bidding Compass.
Has served approximately 2,000 advertisers since 2018, with 393 advertiser customers in FY2023, up from 243 in FY2022.
Business model is based on cost-per-click (CPC) and cost-per-time (CPT) pricing, acting as principal in ad placements and recognizing revenue on a gross basis.
Financial performance and metrics
FY2023 revenue was $28.23M (up 75% YoY), with net income of $0.97M (up from $0.24M in FY2022).
For the six months ended Dec 31, 2023, revenue was $23.50M (up 157% YoY), net income $0.76M (up 70% YoY).
Gross margin improved to 7.3% in FY2023 from 4.0% in FY2022, but declined to 5.1% for the six months ended Dec 31, 2023 due to increased competition and customer rebates.
Cash and cash equivalents were $1.11M as of Dec 31, 2023; company raised $11.04M in its January 2024 IPO.
Major supplier concentration: Ocean Engine accounted for 96% of purchases in FY2023 and 99% in the six months ended Dec 31, 2023.
Use of proceeds and capital allocation
Net proceeds of ~$11.4M from the offering will be allocated: 60% to working capital and general corporate purposes, 30% to acquisitions or investments in complementary technologies/businesses, and 10% to hiring experienced employees for internal controls and compliance.
Plans to invest $2M in R&D for Bidding Compass and recruit 20 new R&D engineers.
Latest events from Haoxi Health Technology
- All AGM proposals, including share consolidation and director re-elections, passed with over 99% approval.HAO
AGM 202510 Jan 2026 - Registering up to $80M in securities, with strong revenue growth and high PRC regulatory risk.HAO
Registration Filing16 Dec 2025 - Raising up to $80M on Nasdaq, the company targets healthcare marketing in China amid regulatory risks.HAO
Registration Filing16 Dec 2025 - FY2025 revenue fell 32% while net income surged to $3.88M, with ongoing regulatory and supplier risks.HAO
Q4 202412 Dec 2025 - Raising $9.09M to expand healthcare-focused digital marketing in China, but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - IPO funds will drive growth and tech investment, but regulatory and supplier risks remain high.HAO
Registration Filing29 Nov 2025 - Chinese healthcare-focused ad tech firm seeks $11.4M via Nasdaq unit offering, CEO retains control.HAO
Registration Filing29 Nov 2025 - Offering 2,093,802 units at $5.97 each, the company targets healthcare ads but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, high regulatory risk, and CEO control define this complex offering.HAO
Registration Filing29 Nov 2025